[TXMD] TherapeuticsMD, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 6 Change: 0.28 (4.9%)
Ext. hours: Change: 0 (0%)

chart TXMD

Refresh chart

Strongest Trends Summary For TXMD

TXMD is in the long-term up 1183% in 12 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: TherapeuticsMD, Inc. operates as a women?s health care product company. The company manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics. It offers prenatal vitamins, iron supplements, vitamin D supplements, natural menopause relief products, and cosmetic stretch mark creams under the vitaMedMD brand, as well as duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. The company also focuses on conducting the clinical trials for hormone therapy pharmaceutical products that are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal dryness. TherapeuticsMD markets its products primarily through a direct national sales force to health care providers, as well as directly through its Website. The company was founded in 2008 and is headquartered in Boca Raton, Florida.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 19.27% Sales Growth - Q/Q5.1% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-66.27% ROE-75.16% ROI
Current Ratio8.7 Quick Ratio8.61 Long Term Debt/Equity Debt Ratio0.13
Gross Margin76.69% Operating Margin-395.98% Net Profit Margin-395.47% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities59.48 M Cash From Investing Activities-40 K Cash From Operating Activities-19.15 M Gross Profit3.43 M
Net Profit-20.89 M Operating Profit-20.92 M Total Assets99.48 M Total Current Assets96.71 M
Total Current Liabilities11.11 M Total Debt Total Liabilities11.77 M Total Revenue4.48 M
Technical Data
High 52 week7.42 Low 52 week3.56 Last close5.18 Last change0.97%
RSI78.48 Average true range0.31 Beta0.08 Volume1.72 M
Simple moving average 20 days21.95% Simple moving average 50 days14.58% Simple moving average 200 days-8.37%
Performance Data
Performance Week16.14% Performance Month33.85% Performance Quart-6.67% Performance Half-22.46%
Performance Year-16.59% Performance Year-to-date35.96% Volatility daily5% Volatility weekly11.17%
Volatility monthly22.9% Volatility yearly79.32% Relative Volume90.61% Average Volume3.32 M
New High New Low

News

2019-03-12 10:27:05 | See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

2019-03-08 07:00:00 | TherapeuticsMD Announces Oral Presentations on BIJUVA and ANNOVERA, and Poster Presentations Related to Menopause Symptoms and Treatments at 2019 ISSWSH/ISSM Joint Meeting

2019-03-05 08:35:00 | Consolidated Research: 2019 Summary Expectations for TherapeuticsMD, Ensco plc, Cray, BeiGene, The Gap, and Nordson — Fundamental Analysis, Key Performance Indications

2019-03-05 08:03:31 | See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

2019-02-28 07:00:00 | TherapeuticsMD Announces Participation in Two Upcoming Investor Conferences

2019-02-25 09:03:02 | TherapeuticsMD TXMD Catches Eye: Stock Jumps 6.1%

2019-02-22 09:11:53 | TherapeuticsMD, Inc. TXMD Q4 2018 Earnings Conference Call Transcript

2019-02-22 08:50:41 | The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data

2019-02-22 01:46:10 | Edited Transcript of TXMD earnings conference call or presentation 21-Feb-19 9:30pm GMT

2019-02-21 17:59:19 | TherapeuticsMD: 4Q Earnings Snapshot

2019-02-21 16:05:00 | TherapeuticsMD Announces Fourth Quarter and Full-Year 2018 Financial Results

2019-02-21 13:55:44 | Is TherapeuticsMD, Inc.’s NASDAQ:TXMD Balance Sheet Strong Enough To Weather A Storm?

2019-02-08 08:04:46 | See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

2019-02-08 07:00:00 | TherapeuticsMD to Report Fourth Quarter and Full Year 2018 Results on February 21, 2019

2019-02-04 21:46:00 | Here's What Pushed TherapeuticsMD 37.8% Higher in January

2019-01-17 08:51:01 | Implied Volatility Surging for TherapeuticsMD TXMD Stock Options

2019-01-17 08:06:19 | See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

2019-01-15 08:03:20 | See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

2019-01-10 15:17:00 | Why TherapeuticsMD's Stock Spiked Today

2019-01-09 08:06:34 | See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

2019-01-03 07:00:00 | TherapeuticsMD Announces Participation at 37th Annual J.P. Morgan Healthcare Conference

2018-12-21 12:40:00 | The Charts of TherapeuticsMD Look Bearish to Me

2018-12-21 07:18:20 | Jim Cramer Weighs In On Palo Alto, Blackstone And More

2018-12-20 18:54:00 | Cramer's lightning round: These cybersecurity stocks are the ones to own in this market

2018-12-20 11:19:29 | Is TherapeuticsMD Inc TXMD A Good Stock To Buy?

2018-12-15 08:03:07 | See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

2018-12-03 08:00:00 | Detailed Research: Economic Perspectives on TESARO, Regeneron Pharmaceuticals, Pool, Zebra Technologies, Cadence Design, and TherapeuticsMD — What Drives Growth in Today's Competitive Landscape

2018-11-19 13:00:44 | Fast-growing pharmaceutical company signs $20M lease to expand Boca Raton HQ

2018-11-12 16:30:00 | TherapeuticsMD Announces Participation in Three Upcoming Investor Conferences

2018-11-08 03:53:28 | Edited Transcript of TXMD earnings conference call or presentation 7-Nov-18 9:30pm GMT

2018-11-07 18:12:37 | TherapeuticsMD: 3Q Earnings Snapshot

2018-11-07 16:05:00 | TherapeuticsMD Announces Third Quarter 2018 Financial Results

2018-11-06 13:12:26 | TherapeuticsMD Inc’s NASDAQ:TXMD Profit Outlook

2018-10-30 07:00:00 | TherapeuticsMD to Report Third Quarter 2018 Financial Results on November 7, 2018

2018-10-29 15:04:00 | Why TherapeuticsMD Is Sinking Despite Sharing Good News

2018-10-29 10:31:02 | TherapeuticsMD TXMD Q3 Earnings Preview: What to Watch Ahead of the Release

2018-10-29 08:00:00 | Today's Research Reports on Trending Tickers: TherapeuticsMD and Horizon Pharma Public

2018-10-29 06:27:37 | U.S. FDA approves TherapeuticsMD's menopause drug

2018-10-29 06:00:00 | TherapeuticsMD Announces FDA Approval of TX-001HR: BIJUVA™ Estradiol and Progesterone Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause

2018-10-25 08:02:20 | See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

2018-10-24 08:25:00 | Consolidated Research: 2018 Summary Expectations for Novavax, Caesars Entertainment, SeaWorld Entertainment, LendingTree, CVS Health, and TherapeuticsMD — Fundamental Analysis, Key Performance Indications

2018-10-16 06:33:00 | 3 Biotechs Awaiting FDA Approval Decisions

2018-10-11 10:30:00 | Cannabis and Biotech Stocks That Have Run Parabolically

2018-09-28 08:32:00 | Today's Research Reports on Trending Tickers: TherapeuticsMD and Endo International

2018-09-28 07:00:00 | TherapeuticsMD Announces Multiple Presentations Related to Imvexxy™ and TX-001HR at the 2018 Annual Meeting of the North American Menopause Society

2018-09-27 16:05:00 | TherapeuticsMD Enters Into Label Discussions for TX-001HR

2018-09-26 08:30:12 | Implied Volatility Surging for TherapeuticsMD TXMD Stock Options

2018-09-25 07:00:00 | TherapeuticsMD to Present at 2018 Cantor Global Healthcare Conference

2018-09-20 07:00:00 | TherapeuticsMD Announces the FDA has Granted AnnoveraTM Marketing Exclusivity as a New Chemical Entity

2018-09-13 07:00:00 | TherapeuticsMD Announces Commercial Availability of Imvexxy™ 4 mcg